NEURONETICS INC (STIM) Stock Fundamental Analysis

NASDAQ:STIM • US64131A1051

1.29 USD
-0.05 (-3.73%)
At close: Feb 20, 2026
1.2834 USD
-0.01 (-0.51%)
After Hours: 2/20/2026, 8:06:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to STIM. STIM was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. STIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year STIM has reported negative net income.
  • STIM had a negative operating cash flow in the past year.
  • STIM had negative earnings in each of the past 5 years.
  • STIM had a negative operating cash flow in each of the past 5 years.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • STIM has a Return On Assets of -30.59%. This is comparable to the rest of the industry: STIM outperforms 43.24% of its industry peers.
  • Looking at the Return On Equity, with a value of -162.68%, STIM is doing worse than 68.65% of the companies in the same industry.
Industry RankSector Rank
ROA -30.59%
ROE -162.68%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • Looking at the Gross Margin, with a value of 50.43%, STIM is in line with its industry, outperforming 45.95% of the companies in the same industry.
  • STIM's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for STIM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for STIM has been increased compared to 1 year ago.
  • Compared to 5 years ago, STIM has more shares outstanding
  • STIM has a better debt/assets ratio than last year.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • STIM has an Altman-Z score of -3.48. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
  • STIM's Altman-Z score of -3.48 is on the low side compared to the rest of the industry. STIM is outperformed by 65.41% of its industry peers.
  • STIM has a Debt/Equity ratio of 2.40. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.40, STIM is doing worse than 83.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Altman-Z -3.48
ROIC/WACCN/A
WACC11.36%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • STIM has a Current Ratio of 2.24. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.24, STIM perfoms like the industry average, outperforming 44.32% of the companies in the same industry.
  • A Quick Ratio of 2.09 indicates that STIM has no problem at all paying its short term obligations.
  • STIM has a Quick ratio of 2.09. This is comparable to the rest of the industry: STIM outperforms 56.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.09
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 33.33% over the past year.
  • STIM shows a strong growth in Revenue. In the last year, the Revenue has grown by 78.62%.
  • The Revenue has been growing slightly by 3.63% on average over the past years.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
Revenue 1Y (TTM)78.62%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%

3.2 Future

  • STIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.70% yearly.
  • Based on estimates for the next years, STIM will show a very strong growth in Revenue. The Revenue will grow by 26.89% on average per year.
EPS Next Y55.83%
EPS Next 2Y28.74%
EPS Next 3Y20.66%
EPS Next 5Y18.7%
Revenue Next Year105.05%
Revenue Next 2Y50.78%
Revenue Next 3Y36.66%
Revenue Next 5Y26.89%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as STIM's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.74%
EPS Next 3Y20.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for STIM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEURONETICS INC

NASDAQ:STIM (2/20/2026, 8:06:13 PM)

After market: 1.2834 -0.01 (-0.51%)

1.29

-0.05 (-3.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)03-17
Inst Owners31.22%
Inst Owner Change102.58%
Ins Owners12.64%
Ins Owner Change3.7%
Market Cap88.35M
Revenue(TTM)129.87M
Net Income(TTM)-44.50M
Analysts82.22
Price Target6.63 (413.95%)
Short Float %25.02%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.21%
Min EPS beat(2)-91.81%
Max EPS beat(2)-0.62%
EPS beat(4)0
Avg EPS beat(4)-52.8%
Min EPS beat(4)-91.81%
Max EPS beat(4)-0.62%
EPS beat(8)2
Avg EPS beat(8)-34.41%
EPS beat(12)5
Avg EPS beat(12)-16.74%
EPS beat(16)8
Avg EPS beat(16)-9.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.93%
Min Revenue beat(2)-3.39%
Max Revenue beat(2)1.52%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-3.39%
Max Revenue beat(4)12.31%
Revenue beat(8)4
Avg Revenue beat(8)-0.03%
Revenue beat(12)6
Avg Revenue beat(12)0.44%
Revenue beat(16)10
Avg Revenue beat(16)1.37%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS1.9
BVpS0.4
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.59%
ROE -162.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.43%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.44%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.09
Altman-Z -3.48
F-Score3
WACC11.36%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
EPS Next Y55.83%
EPS Next 2Y28.74%
EPS Next 3Y20.66%
EPS Next 5Y18.7%
Revenue 1Y (TTM)78.62%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%
Revenue Next Year105.05%
Revenue Next 2Y50.78%
Revenue Next 3Y36.66%
Revenue Next 5Y26.89%
EBIT growth 1Y-23.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.1%
EBIT Next 3Y19.86%
EBIT Next 5Y13.76%
FCF growth 1Y22.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.83%
OCF growth 3YN/A
OCF growth 5YN/A

NEURONETICS INC / STIM FAQ

What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to STIM.


What is the valuation status of NEURONETICS INC (STIM) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.


Can you provide the profitability details for NEURONETICS INC?

NEURONETICS INC (STIM) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NEURONETICS INC?

The Earnings per Share (EPS) of NEURONETICS INC (STIM) is expected to grow by 55.83% in the next year.